Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.
NextCure (NASDAQ:NXTC) reported quarterly losses of $(3.22) per share which beat the analyst consensus estimate of $(3.98) by 1...
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate...
NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) b...
U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.
NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical da...
